Results 211 to 220 of about 1,949,500 (369)

Civil Commitment to Treatment for Substance Use Disorders

Addicta: The Turkish Journal on Addictions, 2023
Hakan Coşkunol
doaj   +1 more source

Sleep phenotyping in a rat model of susceptibility to substance use disorders. [PDF]

PLoS One
Ficiarà E, Faniyan OO, Simayi R, Del Gallo F, Roberto M, Ciccocioppo R, Bellesi M, de Vivo L.   +7 more
europepmc   +1 more source

Discontinuation of Immunotherapy in Patients With Relapsing Myelitis Without AQP4/MOG Antibodies

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT This study assesses the outcomes of immunotherapy discontinuation in patients with relapsing seronegative idiopathic myelitis (SIM), a condition that remains uninvestigated due to its rarity. We reviewed records from 77 patients with relapsing SIM at the National Cancer Center of Korea, focusing on 11 who discontinued treatment after a median ...
Ki Hoon Kim, You‐Ri Kang, Jae‐Won Hyun, Su‐Hyun Kim, Ho Jin Kim   +4 more
wiley   +1 more source

Research Agenda for Substance Use Disorders [PDF]

, 2005

openalex   +1 more source

Malnutrition in Substance Use Disorders: A Critical Issue in Their Treatment and Recovery. [PDF]

Healthcare (Basel)
García-Estrada J, Luquin S, Pesqueda-Cendejas K, Ruiz-Ballesteros AI, Campos-López B, Meza-Meza MR, Parra-Rojas I, González-Castañeda RE, Ramos-Lopez O, De la Cruz-Mosso U.   +9 more
europepmc   +1 more source

Compound Heterozygous MRPS14 Variants Associated With Leigh Syndrome

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT MRPS14 (uS14m) is a nuclear‐encoded ribosomal protein important for mitochondria‐specific translation. To date, only a single individual with a recessive MRPS14‐related disorder (also known as COXPD38) has been reported. We report an additional subject possessing novel compound heterozygous MRPS14 variants (p.Asp37Asn, p.Asn60Asp). The subject
Maria Gabriela Otero, Christina Freeman, Ruchi Shah, Renkui Bai, Hong Cui, Marian Castro, Zachary Myers, Eric Choy, Derek Chan, Molly Easter, Sophia Y. Zhao, Madeline Babros, Ruchi Garg, Matthew Deardorff, Franklin Moser, Tyler Mark Pierson   +15 more
wiley   +1 more source

Theory-based active ingredients of effective treatments for substance use disorders [PDF]

, 2006
Rudolf H. Moos
openalex   +1 more source

Involuntary Treatment for Severe Substance Use Disorders - Issues, Evidence and Considerations for its Use. [PDF]

Can J Psychiatry
Fischer B, Hall W, Jutras-Aswad D, Le Foll B.   +3 more
europepmc   +1 more source

Myostatin Levels in SMA Following Disease‐Modifying Treatments: A Multi‐Center Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study investigated myostatin levels in SMA patients receiving disease‐modifying therapies (DMTs) to understand their relationship with treatment duration and functional status. Methods Our study includes both cross‐sectional and longitudinal analyses of myostatin levels in treated SMA patients.
Fiorella Piemonte, Sara Petrillo, Anna Capasso, Giorgia Coratti, Adele D'Amico, Michela Catteruccia, Maria Carmela Pera, Concetta Palermo, Marika Pane, Emanuela Abiusi, Gianpaolo Cicala, Marianna Villa, Chiara Bravetti, Chiara Arpaia, Agnese Novelli, Salvatore Falqui, Stefania Fiori, Giulia Napoli, Silvia Baroni, Francesco Danilo Tiziano, Enrico Bertini, Giacomo Comi, Stefania Corti, Eugenio Mercuri   +23 more
wiley   +1 more source

Mood and substance use disorders in older adults with HIV/AIDS

, 2004
Judith G. Rabkin, Martin McElhiney, Stephen J. Ferrando   +2 more
openalex   +1 more source